Journal ArticleOPEN ACCESS

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records

  • Polito L
  • Shim J
  • Hurvitz S
  • et al.
JCO Oncology Practice (2023) 19(7) 435-445
DOI: 10.1200/op.22.00565
8Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Survival outcomes are similar for pertuzumab, trastuzumab, and either docetaxel or (nab-)paclitaxel

Cite

CITATION STYLE

APA

Polito, L., Shim, J., Hurvitz, S. A., Dang, C. T., Knott, A., Du Toit, Y., … Swain, S. M. (2023). Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records. JCO Oncology Practice, 19(7), 435–445. https://doi.org/10.1200/op.22.00565

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free